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Background: Airway inflammation and airway remodeling are the key contributors to airway hyperresponsiveness
(AHR), a characteristic feature of asthma. Both processes are regulated by Transforming Growth Factor (TGF)-β.
Caveolin 1 (Cav1) is a membrane bound protein that binds to a variety of receptor and signaling proteins, including
the TGF-β receptors. We hypothesized that caveolin-1 deficiency promotes structural alterations of the airways that
develop with age will predispose to an increased response to allergen challenge.
Methods: AHR was measured in Cav1-deficient and wild-type (WT) mice 1 to 12 months of age to examine the
role of Cav1 in AHR and the relative contribution of inflammation and airway remodeling. AHR was then measured
in Cav1-/- and WT mice after an ovalbumin-allergen challenge performed at either 2 months of age, when
remodeling in Cav1-/- and WT mice was equivalent, and at 6 months of age, when the Cav1-/- mice had established
airway remodeling.
Results: Cav1-/- mice developed increased thickness of the subepithelial layer and a correspondingly increased AHR
as they aged. In addition, allergen-challenged Cav1-/- mice had an increase in AHR greater than WT mice that was
largely independent of inflammation. Cav1-/- mice challenged at 6 months of age have decreased AHR compared
to those challenged at 2 months with correspondingly decreased BAL IL-4 and IL-5 levels, inflammatory cell counts
and percentage of eosinophils. In addition, in response to OVA challenge, the number of goblet cells and α-SMA
positive cells in the airways were reduced with age in response to OVA challenge in contrast to an increased
collagen deposition further enhanced in absence of Cav1.
Conclusion: A lack of Cav1 contributed to the thickness of the subepithelial layer in mice as they aged resulting in
an increase in AHR independent of inflammation, demonstrating the important contribution of airway structural
changes to AHR. In addition, age in the Cav1-/- mice is a contributing factor to airway remodeling in the response
to allergen challenge.Introduction
Asthma is a major public health problem, affecting pa-
tients of all ages from infants to older adults. Morbidity
and mortality are greater in older patients (> 65 yrs) des-
pite a similar prevalence as that in younger asthmatics,
and yet there is limited evidence on how age can* Correspondence: lesaux@uthscsa.edu
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reproduction in any medium, provided the orinfluence the pathogenesis of asthma [1,2]. Older pa-
tients have a larger than predicted reduction in pulmon-
ary function parameters even though physician-assessed
severity, duration of diagnosed asthma, and smoking sta-
tus were not different compared to younger adults. A
significant increase in the comorbid diagnosis of chronic
obstructive pulmonary disease is associated with asthma
in older patients suggesting that long-standing asthma
may lead to irreversible airflow obstruction [3]. Asthma
is characterized by airway hyperresponsiveness (AHR),
an exaggerated narrowing of the airway in response to
stimuli. AHR can reflect asthma severity, and has beenal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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AHR has two distinct components. First, a transient
component occurring after an allergen exposure that is
linked to acute inflammation, second, a more persistent
component, associated with the chronicity of the disease
causing structural changes in the airways known as air-
way remodeling. Several features of airway remodeling
can contribute to AHR, including: increased sensitivity,
hypertrophy and hyperplasia of smooth muscle cells
(SMCs), as well as increased subepithelial fibrosis char-
acterized by increased collagen deposition [8]. The de-
velopment of structural changes persists during and
after acute inflammation in allergic asthma subjects and
in allergen challenge animal models with low inflamma-
tion [9-11]. Some asthma patients develop AHR in asso-
ciation with airway remodeling [12]. Furthermore, severe
asthmatic patients under anti-inflammatory treatments
will present loss in lung function despite inflammation
being controlled [13]. These facts illustrate that underlying
non-inflammatory mechanisms regulate airway structure
and function, which include epithelial thickening and sub-
epithelial collagen deposition.
Caveolin 1 (Cav1) is the main structural and functional
protein of caveolae. These are 10 to 100 nm wide invagina-
tions of the plasma membrane found in many cell types.
Cav1 acts as a scaffolding protein, as well as a regulatory
protein in many signaling cascade protein complexes. Cav1
inhibits the activity of these signaling proteins by binding
and releasing them in a controlled fashion [14]. Cav1 has
been shown to be involved in the regulation of both in-
flammation and fibrosis [15-19]. One of the important
pathways that Cav1 regulates is the Transforming Growth
Factor (TGF)-β pathway. Cav1 binds to and inhibits the
TGF-β type II receptor thus preventing downstream sig-
naling including the phosphorylation of Smad2/3. Others
and our group have demonstrated that Cav1-/- mice have
enhanced Smad2 phosphorylation and altered ECM depos-
ition notably in the lungs [18,19]. We have shown that
aged Cav1-/- mice have decreased lung function (i.e. in-
creased elastance and decreased compliance) mainly due
to an increase in ECM deposition of collagen and elastin
[19]. The regulation of Cav1 has also been shown to be
important in allergic airway disease [20,21]. We have
previously shown that TGF-β signaling is enhanced in
ovalbumin (OVA) challenged Cav1-/- mice leading to
enhanced airway remodeling [21].
TGF-β1 is a pleiotrophic growth factor that participates
in resolution of inflammation, as well as promotion of air-
way remodeling, especially promoting extracellular matrix
(ECM) deposition. Anti-TGF-β1 antibody treatment pre-
vents the progression of airway remodeling following aller-
gen challenge in mice [22]. More surprisingly, enhanced
AHR has been reported in anti-TGF-β antibody treated
OVA challenged mice associated with reduced Smad2phosphorylation, marker of canonical TGF-β signaling
pathway activation [23]. The regulation of TGF-β signaling
activity has been the focus of intensive studies as a poten-
tial therapeutic target but it has not yet been fully
characterized.
This study was designed to evaluate the relationship
between inflammation, structural changes, and lung
function in aged and OVA-challenged mice. We hypoth-
esized that structural alterations of the airways that de-
velop with age in Cav1 deficient mice will predispose
them to an increased response to allergen challenge. The
effect of Cav1-deficiency on airway structure was investi-
gated, and AHR was associated to change in airway
structures.
Material and methods
Animals and OVA-allergen challenge
Wild type C57Bl/6 J (WT) and Cavtm1Mls/J (Cav1-/-) mice
were purchased from The Jackson Laboratory (Bar Harbor,
Maine) to establish our colonies and obtained the appropri-
ate number of animals needed for our experiment. Animal
experiments were conducted using a protocol approved by
the Institutional Animal Care and Use Committee of the
University of Hawaii.
Two- or 6-month-old Cav1-/- and WT female mice were
sensitized by 2 intraperitoneal (IP) injections of OVA ab-
sorbed on alum 12 days apart, followed 2 weeks later by
intranasal challenge with OVA three times over a week.
Measurement of acetylcholine induced AHR and sacrifice
were performed 24 h after the last challenge as described
previously [19]. A group of 2-month old mice was treated
with the Cav1 scaffolding domain or scrambled peptide for
4 weeks as previously described [24].
Measurement of airway hyperresponsiveness (AHR)
AHR was measured using a Flexivent instrument (Scireq
Inc., Montreal, Quebec, Canada) as previously described
[20]. Briefly, mice were anesthetized with ketamine
(100 mg/kg IP) and xylazine (10 mg/kg IP). The trachea
was then surgically exposed and cannulated to allow
ventilation via the Flexivent at 150 breaths/min and a
tidal volume of 7.5 ml/kg. Pancuronium bromide was
administered IP to induce paralysis. Mice were then
given increasing doses of acetylcholine (0.03, 0.1, 0.3,
1.0, 3.2 μg/g) in volume of 2 μl/g of body weight by tail
vein administration at three-minute intervals and total
lung resistance was measured to generate a dose-response
curve. Log PC200 is the log of the dose required to in-
crease resistance 200% over saline baseline. The lower the
LogPC200 value the greater the reactivity [25].
Sample collection
After completion of the AHR measurement, mice were dis-
connected from the animal ventilator and exsanguinated
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lavage (BAL) was performed. Right side lobes were used
for histology and electron microscopy (EM), and sections
were cut longitudinally. EM preparation was carried out as
previously described [19]. The left side lobes was reserved
for RNA and protein extraction.
Morphometric assessment
Photomicrograph images were captured using a Spot
Cooled Color Digital camera (Q Imaging, Burnaby, BC,
Canada). Briefly, a minimum of 5 bronchi, measuring
150–350 μm in luminal diameter with a continuous
smooth muscle layer, were analyzed per mouse for the
parameters described below, using Image Pro-Discovery
software (Media Cybernetics, Silver Spring, MD), cali-
brated with a reference micrometer slide [10,26,27]. The
thickness of the bronchial epithelial layer and subepithelial
deposition of collagen were measured in sections stained
with Masson’s trichrome.
Morphometric α-SMA detection
Formalin-fixed paraffin-embedded sections were stained
for α-smooth muscle actin (α-SMA) using immunohisto-
chemistry and analyzed morphometrically. Primary anti-
body, mouse monoclonal anti α-SMA (Dako, Glostrup,
Denmark), and a FITC labeled secondary antibody was
used to detect α-SMA. The thickness of labeled α-SMA
per length of basement membrane measured in a mini-
mum of 5 bronchi, measuring 150–350 μm in luminal
diameter, were analyzed per mouse for the parameters
described below, using Image Pro-Discovery software
(Media Cybernetics, Silver Spring, MD). Airways were se-
lected and analyzed morphometrically for airway smooth
muscle thickness using the method described above.
Determination of airway inflammation
BAL was collected by injecting and withdrawing one ml
cold phosphate-buffered saline (PBS). Recovered BAL
(70–80%) was centrifuged at 300 g for 10 min. The fluid
was collected for cytokine analyses. Cells were resuspended
in 0.5 ml of PBS and an aliquot was removed to determine
cell concentration using a hemocytometer. The remaining
cells were adhered to glass slides using cytocentrifugation.
Slides were stained using Wright-Giemsa stain and differen-
tial cell counts (minimum of 300 total cells) were obtained
using a Zeiss light microscope. Cytokine levels were mea-
sured in BAL fluid using a Mouse Th1/Th2 Cytokine Kit
Cytometric Bead Array™ (BD Biosciences Pharmingen) ac-
cording to the manufacturer’s instructions.
Airway remodeling assessment
1) Detection of goblet cells: Paraffin-embedded sections
were deparafinized and stained using the standardprocedure of periodic acid Schiff staining as
described by the manufacturer (NovaUltra PAS
Stain Kit, IHC WORLD, Woodstock, MD). We
selected airways of approximately 100-200 μm in
diameter and counted goblet cells in each airway.
Five airways per animals were counted and a
total of 3 animals per group were randomly
selected.
2) Detection of collagen deposition: Paraffin-embedded
lung sections were stained with picrosirius red (PSR)
stain. Briefly, sections were deparafinized and
hydrated to distilled water, then placed in
phosphomolybdic acid 0.2% (cat. No 26356-01
Electron Microscopy Science, Hatfield, PA 19440)
for 5 minutes, and placed directly in sirius red 0.2%
in saturated picric acid (cat. No 26357-02; Electron
Microscopy Science) for 90 minutes. Slides were
washed in 0.01 N hydrochloric acid for 2 minutes
and then placed in 70% ethanol for 45 seconds.
Sections were dehydrated, cleared and mounted.
PSR stained slides were quantified to determine the
percent of collagen in the pulmonary tissue with
Image Pro (Meyer Instruments Houston, TX 77084),
a computer based analytical software. For each
group, the quantification was performed on the
entire upper right lobe of 5 mice.
3) Detection of activation of the canonical TGF-β
signaling pathway. For analyses of levels of phospho-
Smad2 (pSmad2) and total Smad2, whole lung
homogenates were prepared in RIPA buffer in the
presence of HALTTM protease and phosphatase
inhibitor cocktail (#78430 and # 78420, Thermo
Fisher Scientific, Rockford, IL). All antibodies were
purchased from Cell Signaling (Danvers, MA),
except for β-actin (Cytoskeleton Inc; Denver, CO).
Western blot analysis was carried out using the
standard protocol as described previously [28].
Densitometric quantification was carried out by
Image J software to represent the semi-quantitative
protein levels. Relative levels of activated proteins
were obtained as the ratio of phosphorylated
protein: total protein levels. For detection of pSmad2
expression in allergen challenged lung tissue
sections, non-inflated lung tissues were fixed in a
solution of phosphate-buffered saline (PBS)
containing 4% paraformaldehyde. Lungs were
embedded in paraffin and sectioned. Following
routine techniques of deparaffinization, antigen
retrieval and quenching of peroxidase activity, the
slides were incubated with primary pSmad2/3
antibody (cat# 9510S, Cell signaling, Danvers, MA)
at a 1:500 dilution for 12 h, then biotinylated
secondary antibody from VectaStain Elite ABC
Mouse kit (PK-6102, Vector Laboratories
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approximately 100-200 μm in diameter and counted
pSmad2/3 positive cells in each airway. Five airways
per animals were counted and a total of 3 animals
per group were randomly selected.A
C
E
Figure 1 Enhanced AHR in aging Cav1-/- mice. Total lung resistance in r
mice at ages 1 month (A), 3 months old (B), 6 months old (C) and 12 mon
increase in airway resistance over the baseline (log PC200 in μg/mL) was c
Significance was determined by 2 way ANOVA with a Bonferroni Post test
n = 4-9 *p < 0.05. **P < 0.01 and ***P < 0.001 between WT and Cav1-/-.Results
Cav1-deficient mice developed age-dependent
airway hyperresponsiveness
Acetylcholine (Ach)-induced airway reactivity was assessed
in Cav1-/- and WT from ages 1 to 12 months. Over timeB
D
esponse to acetylcholine challenge was measured in Cav1-/- and WT
ths old (D). The log of the dose of acetylcholine required for a 200%
alculated for each mouse (E). Error bars indicate standard error.
(A-D) or a Student’s T test (E) using age matched Cav1-/- and WT mice.
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was no difference between Cav1-/- and WT mice in their
airway response to Ach (Figure 1A, E). By 3 months of
age Cav1-/- mice show differences at high doses of Ach
(Figure 1B), but no change in log PC200 airway reactiv-
ity (Figure 1E). By the time Cav1-/- mice reached the
age of 6 and 12 months AHR had clearly developed
(Figure 1C, D, E). These findings suggest that Cav1-/-
mice developed AHR by 6 months of age independent
of an external injury. We, therefore, investigated airway
structural changes, which can contribute to AHR, tak-
ing place over time in the Cav1-/- mice.Structural changes in the airways in aging Cav1-/- mice
compared to WT animals
The following variables were examined as markers of
structural changes in the airways: thickness of the epithe-
lium and subepithelial basement membrane, subepithelial
collagen deposition, and SMC thickening. To determine
whether increased AHR was associated with early changes
of airway remodeling, epithelial and subepithelial thicken-
ing were evaluated in all age groups. There was no signifi-
cant difference in the epithelial thickness between Cav1-/-
and WT mice at any age (Figure 2A). In contrast, there
was a significant increase in the thickness of the sub-
epithelial matrix in 6- and 12-month-old Cav1-/- mice
compared to the WT mice as measured by morphometric
assessment (Figure 2B) and supported by EM observations
(Figure 2C). Whereas the subepithelial matrix thickness ofA
C
B
Figure 2 Thickening of subepithelial basement membrane. Using Trich
epithelium (A) and thickness of subepithelial basement membrane (B) in C
Significance between age was determined by one-way ANOVA with Tukey
matched Cav1-/- and WT mice was determined by Student’s T test. *p < 0.0
Cav1-/- and WT mice. Magnification is 1,700x. Black staining represents elastWT mice did not significantly increase over time, Cav1-/-
mice showed a steady increase in the thickening of the
subepithelial layer with significantly thicker subepithelial
matrix at 12 months of age than at either 1 or 3 months.
Immunostaining for collagen demonstrated no appreciable
change in Type I or Type III Collagen (Figure 3A and B).
The α-SMA stained SMC layer increased in thickness as
both Cav1-/- and WT mice aged, peaking at 6 months of
age, as measured by morphometric analysis (Figure 3C).
However, the thickness of SMC layer surrounding the air-
way between Cav1-/- and WT animals was never signifi-
cantly different at any time point, indicating that the
change in SMC development is a part of normal growth.
This suggests that an increase in airway smooth muscle
mass is not the cause of increased AHR in the aging
Cav1-/- mice.
This data indicate that cumulative thickening of the
subepithelial matrix layer, but not an increase in smooth
muscle mass, may contribute to the increase in AHR in
Cav1-/- mice over time.AHR after a 1-week OVA challenge in 2- and 6-month-old
in Cav1-/- and WT mice
After it was established that 6-month-old Cav1-/- mice
had increased AHR and increased subepithelial matrix
thickness, an OVA allergen challenge was carried out to
examine the effect of previously established airway struc-
tural changes on AHR, airway remodeling and inflam-
mation triggered by allergen challenge. Two-month oldrome-stained sections, morphometric analysis of thickness of bronchial
av1-/- and WT mice as they age. n = 8-17. Error bars indicate SEM.
’s post test ##p < 0.01, and ###p < 0.001. Significance between age
5, **p < 0.01. (C) TEM micrograph of the airway wall of a 3-month-old
ic fibers.
Figure 3 Airway subepithelial collagen and smooth muscle layer thickness unchanged in Cav1-/- mice. Morphometric quantification of
Collagen1 (A) and Collagen3 (B) immunostaining. Error bars indicate SEM. Significance was determined by ANOVA followed by a Tukey’s post
test. (C) Morphometric analysis of thickness smooth muscle cell layer in Cav1-/- and WT mice as they age. n = 14-21. Error bars indicate standard
error. Significance determined by Student’s T test between age matched in Cav1-/- and WT mice.
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challenge before airway remodeling is established. In
addition, another group of mice, at 6 months of age, also
received a 1-week OVA allergen challenged after we
established the occurrence of airway remodeling in the
knockout mice.
OVA-challenged 6-month-old mice had a lesser AHR
response to allergen than their younger 2-month old
counterparts independent of the presence of Cav1
(Figure 4C). However, both 2-month old and 6-month old
Cav1-/- mice developed more pronounced AHR than age-
matched WT mice in response to allergen challenge. This
indicates that the naturally-occurring airway structural
changes in Cav1-/- mice are not the only contributing fac-
tor to their more pronounced AHR after OVA challenge
(Figure 4A-C).
Treatment of 2-month-old OVA-challenged Cav1-/- mice
with the Cav1 scaffolding domain (CSD) over a 4-week
period prior to challenge was able to partially attenuate the
exaggerated AHR in the Cav1-/- mice, demonstrating the
reversibility of these changes and the specific role of Cav1
(Figure 4D).
Reduced inflammation after a 1-week OVA challenge in
6-month old Cav1-/- compared to WT mice
The degree of inflammation in 2- and 6-month-old OVA-
challenged mice was compared to controls in both Cav1-/-
and WTgroups to determine how these factors influencedAHR. There was no clear correlation between the inflam-
matory cytokine response and the severity of AHR. After
OVA-challenge 2-month old Cav1-/- mice had signifi-
cantly higher levels of IL-4 in the BAL than WT mice
(Table 1). In 6-month-old mice the inflammatory cytokine
response to allergen challenge was less in the Cav1-/- mice
compared to WT with lower levels of IL-13 and IL-17 in
BAL even though AHR in these mice remained higher
than WT (Table 1).
In addition to measuring the BAL cytokine levels, the
number and different types of inflammatory cells in the
BAL were examined. There was no significant difference
in the number of cells in the BAL of WT or Cav1-/- OVA-
challenged mice at 2- and 6 months of age (Table 2). The
total BAL cell count in the 6-month-old OVA-challenged
Cav1-/- mice tended to be less than in the 2-month-old
Cav1-/- mice, however, this was also non-significant. These
data indicate that in the Cav1-/- mice, the increased AHR
is not due to enhanced inflammatory response.
Enhanced collagen deposition and reduced mucus cells in
aged OVA-challenged Cav1-/- compared to WT mice
Features of airway remodeling following allergen chal-
lenge include goblet cell metaplasia, increased number
of α–SMA positive cells, and collagen deposition. Follow-
ing OVA allergen challenge, Cav1-/- mice had less goblet
cell metaplasia compared to WT mice at 2-month and 6-
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Figure 4 Increased AHR in OVA-challenged Cav1-/- mice and partial restoration with CSD. Total lung resistance in response to acetylcholine
challenge was measured in 2 month old (A) or 6 month old (B) Cav1-/- and WT mice after an OVA-allergen challenge. **P < 0.01, ***P < 0.001
between WT and Cav1-/-. n = 4-10. The Log PC200s were calculated from the dose-response curves of OVA challenged Cav1-/- and WT mice (C).
Significance between age was determined by one-way ANOVA with Tukey’s post test. Significance between age matched Cav1-/- and WT mice
was determined by Student’s T test. **P < 0.01 between WT and Cav1-/- , #P < 0.05 between 2 and 6 months, &P < 0.05, &&P < 0.05 between PBS
and OVA. Cav1 scaffolding domain (CSD), or a scrambled peptide (SCR) for control, was administered to Cav1-/- mice in order to restore Cav1
function. An acetylcholine dose response curve was generated to analyze AHR (D). *p < 0.05 by 2 way ANOVA, n = 8. All error bars represent
standard error.
Table 1 BAL cytokine level comparisons between 2- and 6-
month-old mice after a one-week PBS or OVA challenge
WT Cav1-/-
Challenge PBS OVA PBS OVA
2 M old IL-4 10.5 ± 2 921 ± 446* 16 ± 7 1273 ± 1251###
IL-5 94 ± 7 1711 ± 2596 128 ± 34 4434 ± 7265
IL-9 13 ± 3 31 ± 12*** 16 ± 3 25 ± 11
IL-13 19.5 ± 9.5 122 ± 95 15 ± 5 129 ± 180**
IL-17 36.5 ± 2 63 ± 24 38 ± 4 59 ± 24
IgE 0 42 ± 74 0 49 ± 85
6 M old IL-4 75 ± 13 341 ± 244 71 ± 10 520 ± 780
IL-5 22 ± 3 903 ± 176 21 ± 5 542 ± 788
IL-9 27 ± 3.5† 24 ± 14 24 ± 5 21 ± 5
IL-13 34 ± 5.5 176 ± 121** 36 ± 5 45 ± 21##
IL-17 84 ± 19 96 ± 16 82 ± 8 67 ± 14 ##
IgE 0 1.8 ± 1.3 0 53 ± 68.9
*p < 0.05, **p < 0.01, ***p < 0.001 between PBS- and OVA-challenged mice.
##p < 0.01 ###p < 0.001 between Cav1-/- and WT mice, †p < 0.05 between
2- and 6-month old mice. n = 6-12. Values are ng/ml ± standard deviation.
Significance determined by one-way ANOVA with a Tukey post test.
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OVA was associated with reduced goblet cell metaplasia
(2-way ANOVA p-value = 0.0006), however, in absence of
Cav1, the goblet cell population was barely detectable in
6-month-old OVA challenged mice. In contrast, we
detected an increased thickness of α-SMA positive cells
after OVA challenge in the 2-month old Cav1-/- mice
compared to WT. This increase in α-SMA and difference
between Cav1-/- and WT mice was not detected in the 6-
month old animals (Figure 5C, D). Collagen deposition
was also significantly increased in 2-month old Cav1-/-
mice compared to WT mice but was further enhanced in
the 6-month old samples (Figure 5E, F).
As expected based on our previous studies, the level of
activation of the canonical TGF-β signaling pathway was
increased in 2-month Cav1-/- mice after OVA challenge
compared to WT mice as measured by immunohistology
detection of pSmad2. Interestingly, the level of activation
stayed similar in the OVA challenged WT mice compared
to PBS controls but was dramatically reduced in the 6-
month Cav1-/- mice after OVA challenge (Figure 5G, H).
Table 2 BAL inflammatory cell comparison between 2- and 6-month-old mice after a one-week PBS or OVA challenge
2-month old 6-month old
WT Cav1-/- WT Cav1-/-
PBS OVA PBS OVA PBS OVA PBS OVA
BAL Cells Cell/ml 0.8 ± 0.2 6.6 ± 1.5* 0.5 ± 0.2* 17.1 ± 5.3* 0.3 ± 0.1 3.4 ± 0.6* 0.3 ± 0.04 5.2 ± 2.5
Eosinophils% 6.1 ± 2 32.2 ± 2.4* 8.4 ± 1.6 38 ± 2.5* 1.3 ± 0.3 29.5 ± 7.1* 1.5 ± 0.7 19.4 ± 3.4*
Values are ± SEM *p < 0.05 between PBS- and OVA-challenged mice. Significance determined by one-way ANOVA with a Bonferoni post test.
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after OVA-challenge were measured between WT and
Cav1-/- mice and they appear to be diminished with age.
Discussion
Murine models have been useful in studying the mecha-
nisms that contribute to AHR [22-25]. The relative contri-
bution of airway remodeling to AHR is difficult to assess
as most of these models involve an allergic response trig-
gering both inflammation and airway remodeling. In this
study, we explored the inflammatory responses before and
after airway remodeling was established. Our main finding
was that Cav1-/- mice develop AHR as they age. At
6 months of age, the AHR was significantly increased
compared to WT mice, but not at an earlier age. Further-
more, there was also a significantly increased thickening
of the subepithelial matrix layer in Cav1-/- mice as com-
pared to WT mice at 6 months of age. In previous studies,
we have demonstrated by trichrome and picrosirius red
staining that subepithelial collagen deposition is increased
in Cav1-/- mice by the time they are 6 months of age [17].
This suggests that AHR is related to collagen deposition
in the bronchial subepithelial layer. Mathematical model-
ing has demonstrated that relatively minor increases in
the thickness of the small airways can decrease the size of
the airway caliber enough during muscle contraction to
physiologically affect AHR, further supporting our find-
ings [21]. We have also previously demonstrated that
subepithelial collagen deposition contributes to increased
AHR in a chronic OVA allergic airways disease model and
that reversal of subepithelial and total lung collagen by re-
laxin treatment can reduce AHR [26].
The mechanisms for increased collagen deposition in
the setting of Cav1 deficiency are incompletely under-
stood. TGF-β promotes airway remodeling, especially
promoting ECM deposition [10]. In asthmatics, TGF-β
regulated by leukotrienes, can activate lung fibroblasts
and increase collagen deposition [29,30]. We have previ-
ously established that Cav1 was involved in the regula-
tion of TGF-β signaling in murine lungs and that over
time, the absence of Cav1 leads to increased TGF-β sig-
naling and collagen deposition in the parenchyma [17].
In this study we confirmed the increase in pSmad2 signal-
ing in OVA challenged Cav1-/- lungs. For the first time,
we demonstrate the association of Cav1 deficiency withthe development of increased AHR and thickening of the
subepithelial layer. Cav1 interacts with and regulates a
number of proteins in addition to TGF- β that are poten-
tially important for regulation of AHR that we did not in-
vestigate in this study. For example, it has been well
documented that Cav-1 participates in SMC contractility
via Ca2+-dependent mechanisms. Indeed, SMC expressed
Cav-1 and the caveolae contain a number of proteins that
participate in the regulation of Ca2+ [31-34]. Importantly,
Sathish and al. [31] recently showed that Cav-1 regulates
proteins (Orai1) that are important for calcium regulation.
They also showed that an association between Cav1, cal-
cium and inflammation.
After it was established that Cav1-/- mice develop AHR
and subepithelial thickness at 6 months of age, an OVA al-
lergen sensitization and challenge was carried out at
2 months of age (before airway remodeling is established)
and at 6 months of age (after airway remodeling is estab-
lished) to explore differences in the inflammatory re-
sponse. OVA challenge induced markedly elevated BAL
cytokine levels in 2-month old WT and Cav1-/- mice, but
reduced cytokine levels in 6-month Cav1-/- mice after the
OVA allergen challenge. In a similar fashion, 6-month
Cav1-/- mice had a decreased number of inflammatory
cells and percentage of eosinophils in the BAL after the
OVA allergen challenge compared to 2-month Cav1-/-
mice. Increased number of mucous cells has been associ-
ated with increased IL-13, inflammation and eosinophilia
[35]. Importantly, both age and Cav1 expression influence
these parameters of response to allergen challenge. In our
study, eosinophilia and levels of IL-5 decreased in older
mice and correlated with reduced mucous cell metaplasia.
Six-month-old OVA challenged Cav1-/- mice reduced IL-
13 in the BAL corresponding to few mucous cells. Few re-
ports investigating airway inflammation in aged sensitized
and challenged mice are available and even less on airway
remodeling. The decrease in eosinophilia and overall cyto-
kine level in aged mice both WT and Cav1-/- mice was
consistent with 2 of 3 previous studies using similar aller-
gen challenge protocols [36-38]. Our findings suggest that
the AHR observed in 6-month-old Cav1-/- mice is inde-
pendent of inflammation and more closely related to in-
creased collagen around the airways. The work from
Busse et al. also argues against a direct relationship between
pulmonary inflammation or eosinophils and increased
WT 1w OVA Cav1-/-1w OVA
2m
6m



















Figure 5 Alterations of the airway remodeling features in mice after OVA challenge in Cav1-/- mice. Representative pictures of 1
week-OVA challenged WT and Cav1-/- mouse lung sections. (A,B.) Goblet cells metaplasia was detected using Periodic Acid Schiff staining.
Positive cells (indicated by arrows) were counted in airways of 100-200 μm in an average of 5 airways per animals is reported (Bar graph). (C,D.)
Detection of α-SMA positive cells by immunohistochemistry and reporting the surface of positive staining relative to the length of basement
membrane (Bar graph). (E,F.) Detection of collagen depositon around the airways using Picrosirius red staining and quantification of the relative
amount of collagen deposition (Bar graph). (G,H.) Detection of pSmad2 using immunohistochemistry. Activation of the canonical TGF–β signaling
pathway was also determined by western blot. Densitometric quantitations were carried out using the whole lung homogenates of WT and
Cav1-/- mice after a 1-week OVA challenge. Values are represented as relative protein levels of pSmad2 to total Smad2 (Bar graph). For all the
measurement, * < p 0.05 represents significance by 2-way ANOVA between WT and Cav1-/- mice for the same age group, and # < p 0.05 represents
significance by 2-way ANOVA between same age group for WT and Cav1-/- mice.
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In asthmatic patients, the persistence of AHR can be
associated with airway remodeling after the resolution of
inflammation [6]. In addition, in mouse models, prolonged
allergen challenge leads to persistent changes in the air-
ways despite discontinuation of the allergen challenge
[7,8]. These studies demonstrate a role of airway remodel-
ing in AHR beyond the immediate inflammatory response.
Other genetically engineered mouse models also point to-
ward the importance of airway remodeling independent of
inflammation [7,8]. For example, relaxin-deficient mice
also show similar results, where an increase in airway re-
modeling leads to increased AHR [7,8,26].
The timing of airway remodeling development in asthma
is an area of increasing interest. Evidence suggests that re-
modeling of airways may develop long before symptoms of
asthma and inflammation appear [29]. In our study, older
mice in both groups had less AHR and the BAL cytokines
tended to be present at lower levels after the OVA allergen
challenge. This suggests that some alterations in lung re-
sponse to allergen challenge as the mice age were inde-
pendent of the presence or absence of Cav1. Nevertheless,
the reduction in inflammation was more prominent in the
Cav1-/- mice with greater reductions in eosinophils and IL-
13. The decrease in inflammation in 6-month-old mice can
account for the decrease in AHR seen in these mice com-
pared to 2-month-old mice. Indeed, we demonstrated a
decrease in the IL-4 levels in 6-month-old mice versus 2-
month-old mice, and other studies have shown that treat-
ment of sensitized mice with anti-IL-4 antibody prior to
antigen stimulation reduces antigen-induced AHR, eosino-
philia, and goblet cell metaplasia [39]. In addition, IL-4 can
induce AHR and goblet cell metaplasia independent of IL-
13 [31]. Despite the greater decrease in inflammation in the
Cav1-/- mice as they aged, the AHR of the Cav1-/- remained
greater than age-matched WT indication that remodeling
rather than inflammation may play a role in the elevated
AHR in 6-month-old OVA-challenged Cav1-/- mice.
These findings have important implications, as they
open avenues for possible therapeutic interventions to
prevent the development of airway remodeling. Our data
are supportive of the beneficial effects on airway remod-
eling after treatment with Cav1 scaffolding domain pep-
tide. In addition, in other studies using relaxin-deficient
mice, it has been demonstrated that treatment with relaxin
is capable of reversing established airway remodeling and
AHR [27]. These studies suggest that the development of
anti-fibrotic therapies that could potentially prevent lung
function decline associated with airway remodeling is war-
ranted. This approach may be especially relevant in severe
asthma, where well-established treatments with inhaled
corticosteroids have limited efficacy in the control of air-
way remodeling development and reversibility [10,29].Even though subepithelial fibrosis is an established char-
acteristic in airway remodeling, other studies have demon-
strated that changes in myocytes and globet cells may also
induce AHR. In this murine model, we identified an in-
crease in subepithilial thickening as the main contributor
of AHR in Cav1-/- mice, but because asthma is a heteroge-
neous disease, other cellular components may still play an
important role in airway remodeling and AHR.
In conclusion, our findings demonstrate that Cav1 de-
ficiency is associated with airway remodeling and the de-
velopment of AHR. The airway remodeling progressed
with age. Inflammation appears not to be required for
the development of these age-related changes in Cav1
deficient mice. Cav1 may play a role, possibly through
the TGF-β pathway, in the prevention of the develop-
ment of subepithelial fibrosis and airway remodeling.
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